丹参川芎嗪注射液对急性冠脉综合征患者血清超敏C反应蛋白及心功能的影响

目的：观察丹参川芎嗪注射液治疗急性冠脉综合征（ACS）患者的临床疗效和对ACS患者血清超敏C-反应蛋白（hs—CRP）及射血分数（EF）的影响。方法：98例ACS患者随机分为对照组和治疗组，对照组给予常规西药治疗，治疗组在常规西药治疗基础上加用丹参川芎嗪注射液，另选择健康体检者60例作为正常对照组。于治疗前及治疗10d后测定并比较血清hs-CRP水平，行彩超检查记录射血分数，评价心功能，对疗效进行比较。结果：治疗组心绞痛缓解有效率（96．7％）明显高于对照组（79．2％）（P〈0．01）；对照组、治疗组治疗前、后血清hs-CRP水平均明显高于正常对照组（P〈0．01），治疗组治疗后血清hs—CRP水平明显低于治疗前和对照组（P〈0．05～0．01）；对照组、治疗组治疗后EF明显高于治疗前（P〈0．01），两组间差异无统计学意义（P〉0．05）。结论：丹参川芎嗪注射液可有效地缓解ACS患者的心绞痛症状，并能降低血清hs-CRP水平。

Influence of danshen ligustrazin for injection on serum high-sensitivity C-reactive protein and cardiac function of patients with acute coronary syndrome

Objective:To investigate the effect of danshen ligustrazin for injection on the treatment of acute coronary syndrome (ACS) and the influence on serum high-sensitivity C-reactive protein (hs-CRP) and cardiac ejection fraction (EF). Methods:Ninety-eight patients with ACS were divided randomly into group A and B,and 60 health subjects were selected as group C,patients in group A were treated with western medicine,patients in group B were treated with western medicine as group A and danshen ligustrazin for injection. All patients were determined serum hs-CRP and evaluated ejection fraction with echocardiography 10 d before and after treatment respectively,subjects in group C were determined serum hs-CRP,the parameters determined above were studied. Results:The remission rate of angina pectoris in group B was significantly higher than that in group A (96.7% vs. 79.2%,P<0.01); the serum hs-CRP in group B after treatment was significantly lower than that in group B before treatment and in group C (P<0.05); ejection fractions in group B and A after treatment were significantly higher than that before treatment (P<0.01),the difference between group A and B was no significant (P>0.05). Conclusion:Danshen ligustrazin for injection can effectively alleviate angina pectoris of patients with ACS and reduce serum levels of hs-CRP.